What is the bonus history of the Shree Ganesh Rem?

Shree Ganesh Remedies' recent bonus history includes a 1:5 bonus announced on November 1, 2021, with a record date of November 2, 2021, and a previous 3:26 bonus issued on October 6, 2020, with a record date of October 7, 2020.

Shree Ganesh Remedies has a notable bonus history. The most recent bonus issue was a 1:5 ratio, which was announced with an ex-date of November 1, 2021, and the record date was November 2, 2021. Prior to that, the company had a bonus issue with a ratio of 3:26, which had an ex-date of October 6, 2020, and a record date of October 7, 2020. If you have any more questions about the company or its financials, feel free to ask!

Has Shree Ganesh Rem declared dividend?

Shree Ganesh Remedies Ltd has declared a 5% dividend, amounting to 0.5 per share, with an ex-date of September 7, 2023. Despite this, the recent total returns show declines over shorter periods, while longer-term performance remains strong.

Shree Ganesh Remedies Ltd has declared a 5% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 5%<BR>- Amount per share: 0.5<BR>- Ex-date: 07 Sep 2023<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -14.84%, with a dividend return of 0%, resulting in a total return of -14.84%.<BR><BR>Over the past year, the price return was -24.98%, with a dividend return of 0%, leading to a total return of -24.98%.<BR><BR>In the 2-year period, the price return was 62.3%, with a dividend return of 0.14%, resulting in a total return of 62.44%.<BR><BR>For the 3-year period, the price return was 142.1%, with a dividend return of 0.45%, leading to a total return of 142.55%.<BR><BR>In the 4-year period, the price return was 127.4%, with a dividend return of 0.85%, resulting in a total return of 128.25%.<BR><BR>Over the last 5 years, the price return was 940.28%, with a dividend return of 6.40%, leading to a total return of 946.68%.<BR><BR>Overall, while Shree Ganesh Remedies Ltd has declared a dividend, the recent total returns show significant declines over shorter periods, contrasting with strong performance over the longer term. The dividend yield remains at 0%, indicating that the recent dividends have not contributed to returns in the short term.

Who are the peers of the Shree Ganesh Rem?

Peers of Shree Ganesh Rem include Shukra Pharma, Wanbury, NGL Fine Chem, and others. Shree Ganesh Rem has an average growth rating and a 1-year return of -25.76%, higher than NGL Fine Chem but lower than its other peers.

Peers: The peers of Shree Ganesh Rem are Shukra Pharma., Wanbury, NGL Fine Chem, Kopran, Kilitch Drugs, Kerala Ayurveda, Venus Remedies, Ind-Swift Labs., Sakar Healthcare, and Accent Microcell.<BR><BR>Quality Snapshot: Excellent management risk is observed at NGL Fine Chem and Venus Remedies, while Average management risk is found at Shukra Pharma., Wanbury, Kopran, and the rest. Below Average management risk is noted at Kilitch Drugs, Kerala Ayurveda, Ind-Swift Labs., and the rest. Growth is Excellent at Kilitch Drugs, Good at Shukra Pharma. and Accent Microcell, Average at Shree Ganesh Rem, Wanbury, Kopran, Venus Remedies, and the rest, and Below Average at NGL Fine Chem, Kerala Ayurveda, Ind-Swift Labs., and Sakar Healthcare. Capital Structure is Excellent at NGL Fine Chem and Venus Remedies, Good at Shukra Pharma., Kopran, Kilitch Drugs, and Shree Ganesh Rem, Average at Sakar Healthcare, and Below Average at Wanbury, Kerala Ayurveda, and Ind-Swift Labs.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Shukra Pharma. at 146.07%, while the lowest is NGL Fine Chem at -47.08%. Shree Ganesh Rem's 1-year return is -25.76%, which is higher than NGL Fine Chem but lower than all other peers. Additionally, NGL Fine Chem, Ind-Swift Labs., and Sakar Healthcare have negative six-month returns.

Who are in the management team of Shree Ganesh Rem?

As of March 2022, the management team of Shree Ganesh Rem includes Chairman & Managing Director Chandubhai Kothia, Whole-time Directors Gunjan and Parth Kothia, and several independent directors, with varying remuneration levels. Notably, Chandubhai Kothia earns INR 1.02 crore, while other directors have lower or no reported remuneration.

As of March 2022, the management team of Shree Ganesh Rem includes the following individuals:<BR><BR>1. **Chandubhai Kothia** - Chairman & Managing Director, with a remuneration of INR 1.02 crore.<BR>2. **Gunjan Chandulal Kothia** - Whole-time Director, with a remuneration of INR 51.0 lakhs.<BR>3. **Parth Chandulal Kothia** - Whole-time Director, with a remuneration of INR 42.0 lakhs.<BR>4. **Priyam Surendra Shah** - Independent Director, with a remuneration of INR 30,000.<BR>5. **Jayesh Savjani** - Independent Director, with a remuneration of INR 30,000.<BR>6. **Vaishaliben Kanjibhai Vadodariya** - Independent Director, with a remuneration of INR 30,000.<BR>7. **Parul Sahani** - Director, with no remuneration reported.<BR>8. **Maulikkumar Sudani** - Independent Director, with no remuneration reported.

What does Shree Ganesh Rem do?

Shree Ganesh Remedies Ltd manufactures pharmaceutical intermediates and fine chemicals, classified as a Micro Cap company with a market cap of INR 765 Cr. As of March 2025, it reported net sales of 244 Cr and a net profit of 66 Cr.

Overview: <BR>Shree Ganesh Remedies Ltd is engaged in the manufacturing of pharmaceutical intermediates and fine chemicals, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History: <BR>Shree Ganesh Remedies Ltd was originally incorporated as a Private Limited Company on April 27, 1995, in Ahmedabad, Gujarat. It was later converted into a Public Limited Company and renamed on July 28, 2017. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 244 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 66 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 765 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 34.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.09 <BR>Return on Equity: 17.35% <BR>Price to Book: 5.74 <BR><BR>Contact Details: <BR>Address: Plot No 6011, GIDC Ankleshwar Gujarat : 393002 <BR>Tel: 91-2646-227777 <BR>Email: investors@ganeshremedies.com <BR>Website: http://www.ganeshremedies.com

Who are the top shareholders of the Shree Ganesh Rem?

The top shareholder of Shree Ganesh Rem is Chandulal Manubhai Kothia, holding 48.76%, followed by public shareholder Gunjan Jayantibhai Dhorajiya at 1.7%. Individual investors own 24.89%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Shree Ganesh Rem include the promoters, with Chandulal Manubhai Kothia being the largest shareholder, holding 48.76% of the company. The highest public shareholder is Gunjan Jayantibhai Dhorajiya, who holds 1.7%. Additionally, individual investors collectively hold 24.89% of the shares. There is also one foreign institutional investor (FII) that holds a very small percentage, at 0.01%. Notably, there are no pledged promoter holdings and no mutual funds currently invested in the company.

How big is Shree Ganesh Rem?

As of 24th July, Shree Ganesh Remedies Ltd has a market capitalization of 756.00 Cr, with Net Sales of 108.59 Cr and a Net Profit of 23.07 Cr reported in the latest four quarters.

As of 24th July, Shree Ganesh Remedies Ltd has a market capitalization of 756.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 108.59 Cr and a Net Profit of 23.07 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 122.10 Cr and Total Assets valued at 170.94 Cr.

Are Shree Ganesh Rem latest results good or bad?

The latest results for Shree Ganesh Remedies are disappointing, with a 31.95% decline in Profit Before Tax and a 20.95% drop in net sales year-on-year, indicating significant operational challenges for the company.

The latest results for Shree Ganesh Remedies indicate a challenging period for the company. For the quarter ending June 2025, the company reported a significant decline in key financial metrics. Profit Before Tax (PBT) decreased by 31.95% year-on-year to Rs 3.94 crore, while Profit After Tax (PAT) fell by 25.8% to Rs 3.45 crore. <BR><BR>Net sales also saw a decline of 20.95% year-on-year, totaling Rs 49.10 crore for the latest six months. Additionally, the operating profit (PBDIT) dropped to Rs 7.30 crore, marking the lowest level in the last five quarters, and the operating profit margin fell to 29.59%. The earnings per share (EPS) decreased to Rs 2.69, reflecting reduced profitability for shareholders.<BR><BR>Overall, these results suggest that Shree Ganesh Remedies is facing significant operational challenges, and the financial performance can be characterized as disappointing.

Is Shree Ganesh Rem technically bullish or bearish?

As of September 25, 2025, the market trend has shifted to a moderately strong bearish stance, indicated by bearish daily moving averages and Bollinger Bands, despite mixed signals from the MACD and KST across different time frames.

As of 25 September 2025, the technical trend has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the daily moving averages indicating bearishness, and both the weekly and monthly Bollinger Bands also signaling bearish trends. The MACD shows a mildly bullish signal on the weekly but is mildly bearish on the monthly, suggesting mixed signals across time frames. The KST aligns with this by being mildly bullish weekly and mildly bearish monthly. Overall, the bearish trend is reinforced by the recent price decline and underperformance compared to the Sensex over multiple periods.

Is Shree Ganesh Rem overvalued or undervalued?

As of October 10, 2025, Shree Ganesh Rem is fairly valued with a PE ratio of 29.32 and an EV to EBITDA of 17.00, but has underperformed with a year-to-date stock return of -21.58% compared to the Sensex's 5.58%.

As of 10 October 2025, the valuation grade for Shree Ganesh Rem has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 29.32, an EV to EBITDA of 17.00, and a ROCE of 19.10%. In comparison to its peers, Sun Pharma has a higher PE ratio of 34.96 and an EV to EBITDA of 23.7, while Dr. Reddy's Labs shows a more attractive valuation with a PE of 18.58 and an EV to EBITDA of 12.26.<BR><BR>Despite the recent valuation adjustment, Shree Ganesh Rem has underperformed in the short term, with a year-to-date stock return of -21.58% compared to a Sensex return of 5.58%. This performance suggests that while the stock may be fairly valued, it faces challenges in the current market environment.

When is the next results date for Shree Ganesh Rem?

The next results date for Shree Ganesh Rem is 07 November 2025.

The next results date for Shree Ganesh Rem is scheduled for 07 November 2025.

Should I buy, sell or hold Shree Ganesh Rem?

How has been the historical performance of Shree Ganesh Rem?

Shree Ganesh Rem's historical performance shows fluctuating trends, with net sales and profits declining from March 2024 to March 2025, despite growth in total assets. Recent results indicate a decrease in profitability and cash flow, contrasting with earlier growth.

Answer:<BR>The historical performance of Shree Ganesh Rem shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Shree Ganesh Rem's net sales decreased from INR 125.90 crore in March 2024 to INR 108.60 crore in March 2025, following a significant rise from INR 49.08 crore in March 2021. The total operating income mirrored this trend, remaining at INR 108.60 crore in March 2025, down from INR 125.90 crore in the previous year. The company's operating profit (PBDIT) also saw a decline to INR 42.95 crore in March 2025 from INR 44.88 crore in March 2024, although it had increased from INR 15.74 crore in March 2021. Profit before tax decreased to INR 31.27 crore in March 2025 from INR 38.16 crore in March 2024, while profit after tax followed suit, dropping to INR 23.07 crore from INR 28.11 crore. The company's total assets grew to INR 191.94 crore in March 2025 from INR 170.94 crore in March 2024, and total liabilities increased to INR 191.94 crore from INR 170.94 crore in the same period. Cash flow from operating activities remained stable at INR 30.00 crore in both March 2025 and March 2024, but the net cash outflow was recorded at INR 5.00 crore in March 2025, contrasting with a net inflow of INR 7.00 crore in March 2024. Overall, while Shree Ganesh Rem has shown growth in certain areas over the years, recent performance indicates a decline in profitability and cash flow.

Which are the latest news on Shree Ganesh Rem?

Why is Shree Ganesh Rem falling/rising?

As of 04-Dec, Shree Ganesh Remedies Ltd's stock price is currently at Rs. 466.95, reflecting a 2.42% increase after hitting a 52-week low earlier in the day. Despite today's rise and sector outperformance, the stock has seen significant declines over the past month and year-to-date, indicating a longer-term downward trend.

As of 04-Dec, Shree Ganesh Remedies Ltd's stock price is rising, currently at Rs. 466.95, which reflects an increase of Rs. 11.05 or 2.42%. This rise is notable as the stock has recently hit a new 52-week low of Rs. 423 earlier in the day, indicating a significant intraday fluctuation. Despite the stock's current upward movement, it has experienced a decline of 5.96% over the past month and a substantial year-to-date drop of 26.80%. <BR><BR>Today's performance shows that the stock has outperformed its sector by 2.13%, which may contribute to the positive sentiment around its price increase. However, it is important to note that the stock is trading below its moving averages across various time frames, suggesting a longer-term downward trend. Additionally, while there has been a slight increase in investor participation, with delivery volume remaining stable, the overall liquidity remains adequate for trading.<BR><BR>In summary, the stock's rise today can be attributed to a brief recovery after hitting a low, alongside sector outperformance, despite the broader context of its recent poor performance over longer periods.